StockNews.AI
CODX
StockNews.AI
159 days

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

1. CODX will release Q4 and full year results on March 27, 2025. 2. A conference call will follow the results announcement to discuss financials. 3. The management team includes CEO Dwight Egan and CFO Brian Brown. 4. CODX specializes in molecular diagnostics leveraging patented technology. 5. Webcast details for financial results are available on CODX's website.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results can influence investor sentiment positively. Previous earnings announcements have historically shown significant market reactions for CODX.

How important is it?

The financial results release might significantly guide future investor actions on CODX, due to its impact on revenue forecasts.

Why Short Term?

Immediate impact expected from the results announcement and related investor discussions. Earnings typically affect stock prices shortly after release.

Related Companies

NVTALABDQDEL
, /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagnostics.com on the Events & Webcasts page Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international) If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc.Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. SOURCE Co-Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News